Figure 1: Adjuvants have a profound impact on the peak and magnitude of the long-lived antibody response. | Scientific Reports

Figure 1: Adjuvants have a profound impact on the peak and magnitude of the long-lived antibody response.

From: Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate

Figure 1

Mice were immunized i.m. with 1 μg Pfs25 alone (Pfs25) or Pfs25 conjugated to EPA (Pfs25-EPA) formulated in various adjuvants on day 0 and day 28. (a) Schema of immunization strategy. Mice were primed in the left leg and boosted, contralaterally, in the right leg. All mice were primed and boosted with the same antigen/adjuvant combination with the exception of the CFA/IFA group where mice were primed with CFA (s.c) and boosted with IFA (i.p.). (b–f) Anti-Pfs25 IgG ELISA titers collected at various time points after immunization with Pfs25-EPA and saline (b), Alhydrogel (c), CFA/IFA (d), CpG in SE (e), and GLA-LSQ (f). Shown is the geometric mean with 95% confidence interval from 5–10 mice per group. (g) Representative ELISPOTs showing ASC producing IgG antibodies reactive against Pfs25. Number of cells plated is noted to the right of the image. No cells refers to the negative control where no cells were plated. (h) Number of ASCs specific to Pfs25 in the bone marrow of mice on day 245 calculated via ELISpot. Shown is the mean ± SEM, n = 15–20 mice per group. (**P < 0.01; Mann-Whitney U test). Data are from one experiment and representative of 3 independent experiments.

Back to article page